Pharsight

Ozempic patents expiration

OZEMPIC's oppositions filed in EPO
OZEMPIC Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8536122 NOVO Acylated GLP-1 compounds
Mar, 2026

(2 years from now)

US8129343 NOVO Acylated GLP-1 compounds
Dec, 2031

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6899699 NOVO Automatic injection device with reset feature
Jan, 2022

(1 year, 8 months ago)

US9486588 NOVO Automatic injection device with reset feature
Jan, 2022

(1 year, 8 months ago)

US8672898 NOVO Automatic injection device with reset feature
Jan, 2022

(1 year, 8 months ago)

US8579869 NOVO Needle mounting system and a method for mounting a needle assembly
Jun, 2023

(2 months ago)

US7762994 NOVO Needle mounting system and a method for mounting a needle assembly
May, 2024

(7 months from now)

US8114833 NOVO Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
Aug, 2025

(1 year, 10 months from now)

US11446443 NOVO Injection device with torsion spring and rotatable display
Oct, 2025

(2 years from now)

US8684969 NOVO Injection device with torsion spring and rotatable display
Oct, 2025

(2 years from now)

US11311679 NOVO Automatic injection device with a top release mechanism
Jan, 2026

(2 years from now)

US9108002 NOVO Automatic injection device with a top release mechanism
Jan, 2026

(2 years from now)

US9861757 NOVO Injection device with an end of dose feedback mechanism
Jan, 2026

(2 years from now)

US10357616 NOVO Injection device with an end of dose feedback mechanism
Jan, 2026

(2 years from now)

US9616180 NOVO Automatic injection device with a top release mechanism
Jan, 2026

(2 years from now)

US10376652 NOVO Automatic injection device with a top release mechanism
Jan, 2026

(2 years from now)

US8920383 NOVO Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left
Jul, 2026

(2 years from now)

US9775953 NOVO Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left
Jul, 2026

(2 years from now)

US10220155 NOVO Syringe device with a dose limiting mechanism and an additional safety mechanism
Jul, 2026

(2 years from now)

US11097063 NOVO Syringe device with a dose limiting mechanism and an additional safety mechanism
Jul, 2026

(2 years from now)

USRE46363 NOVO Dial-down mechanism for wind-up pen
Aug, 2026

(2 years from now)

US9687611 NOVO Injection device with torsion spring and rotatable display
Feb, 2027

(3 years from now)

US9457154 NOVO Injection device with an end of dose feedback mechanism
Sep, 2027

(4 years from now)

US9132239 NOVO Dial-down mechanism for wind-up pen
Feb, 2032

(8 years from now)

US10335462 NOVO Use of long-acting GLP-1 peptides
Jun, 2033

(9 years from now)

Ozempic is owned by Novo.

Ozempic contains Semaglutide.

Ozempic has a total of 25 drug patents out of which 4 drug patents have expired.

Expired drug patents of Ozempic are:

  • US6899699
  • US9486588
  • US8672898
  • US8579869

Ozempic was authorised for market use on 05 December, 2017.

Ozempic is available in solution;subcutaneous dosage forms.

Ozempic can be used as a method of treating type 2 diabetes comprising administering semaglutide once weekly in a amount of 1.0 mg to a subject in need thereof, ozempic is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

The generics of Ozempic are possible to be released after 21 June, 2033.

Drug Exclusivity Drug Exclusivity Expiration
New Indication (I) Jan 16, 2023
New Dosing Schedule (D) Mar 28, 2025

Drugs and Companies using SEMAGLUTIDE ingredient

Market Authorisation Date: 05 December, 2017

Treatment: A method of treating type 2 diabetes comprising administering semaglutide once weekly in a amount of 1.0 mg to a subject in need thereof; Ozempic is indicated as an adjunct to diet and exercise to imp...

Dosage: SOLUTION;SUBCUTANEOUS

How can I launch a generic of OZEMPIC before it's drug patent expiration?
More Information on Dosage

OZEMPIC family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic